Humana Inc.
422.07USD
+1.1000 (+0.26%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on HUM.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$1▼ | -$0.14 | 0 | 4 |
| Next quarter | -$7.86▲ | -$8.17 | 3 | 1 |
| Current year | $9.16▲ | $8.96 | 5 | 1 |
| Next year | $17.09▲ | $16.03 | 6 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $7 | $7.61 | +0.61 (+8.8%) |
| 2026-03-31 | $10.2 | $10.31 | +0.11 (+1.1%) |
| 2025-12-31 | -$3.99 | -$3.96 | +0.03 (+0.7%) |
| 2025-09-30 | $2.83 | $3.24 | +0.41 (+14.6%) |
438 ratings from 42 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Mizuho | Maintained | Outperform | $468 $495 | Oct 13, 2026 |
| UBS | Maintained | Neutral | $405 $495 | Oct 12, 2026 |
| Truist Securities | Maintained | Hold | $415 $475 | Oct 12, 2026 |
| Oppenheimer | Maintained | Outperform | $475 $525 | Oct 12, 2026 |
| Raymond James | Upgraded from Market Perform | Outperform | $520 | Oct 12, 2026 |
| Barclays | Maintained | Overweight | $515 $582 | Oct 9, 2026 |
| Oppenheimer | Maintained | Outperform | $405 $475 | Oct 9, 2026 |
| Baird | Upgraded from Neutral | Outperform | $390 $596 | Oct 9, 2026 |
| Cantor Fitzgerald | Upgraded from Neutral | Overweight | $300 $460 | Oct 7, 2026 |
| Barclays | Upgraded from Equal-Weight | Overweight | $407 $515 | Sep 25, 2026 |
| JP Morgan | Maintained | Neutral | $316 $393 | Aug 10, 2026 |
| Morgan Stanley | Upgraded from Underweight | Equal-Weight | $249 $370 | Aug 5, 2026 |
| TD Cowen | Maintained | Hold | $350 $370 | Jul 31, 2026 |
| Barclays | Maintained | Equal-Weight | $344 $407 | Jul 31, 2026 |
| UBS | Maintained | Neutral | $320 $405 | Jul 30, 2026 |
| Evercore ISI Group | Upgraded from In-Line | Outperform | $430 $480 | Jul 30, 2026 |
| Guggenheim | Maintained | Buy | $269 $471 | Jul 30, 2026 |
| Raymond James | Downgraded from Outperform | Market Perform | — | Jul 30, 2026 |
| TD Cowen | Maintained | Hold | $211 $350 | Jul 14, 2026 |
| Truist Securities | Maintained | Hold | $320 $415 | Jul 14, 2026 |
| Wells Fargo | Upgraded from Equal-Weight | Overweight | $227 $502 | Jul 13, 2026 |
| RBC Capital | Maintained | Sector Perform | $246 $415 | Jul 9, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $264 $300 | Jul 7, 2026 |
| B of A Securities | Maintained | Neutral | $340 $380 | Jun 24, 2026 |
| Evercore ISI Group | Maintained | In-Line | $250 $370 | Jun 11, 2026 |
71 filings from 24 insiders · 0 buy / 0 sell over 6m
Officers and directors of HUM, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HILZINGER KURT JDirector | GrantRestricted Stock Units | 238 | $384.91 | $92k | Sep 30, 2026 |
| Nundy ShantanuOfficer, Chief Medical Officer | Grant | 2.5k | — | — | Sep 1, 2026 |
| SMITH PAUL JOHNDirector | Grant | 544 | — | — | Jul 31, 2026 |
| CRAWFORD FREDERICK JOHNDirector | Grant | 544 | — | — | Jul 31, 2026 |
| DINTENFASS DAVIDOfficer | Grant | 11.3k | — | — | May 1, 2026 |
| MEHTA JAPANChief Technology Officer | Grant | 9.4k | — | — | May 1, 2026 |
| MELLET CELESTEChief Financial Officer | Grant | 15.4k | — | — | May 1, 2026 |
| MARTIN AARONOfficer | Grant | 8.2k | — | — | May 1, 2026 |
| FIELD ROBERT STUARTDirector | Grant | 852 | — | — | May 1, 2026 |
| VENTURA JOSEPH CHRISTOPHEROfficer | Grant | 10.3k | — | — | May 1, 2026 |
| O'HARA MICHELLE A.Officer | Grant | 10.5k | — | — | May 1, 2026 |
| SHETTY SANJAY KOfficer | Grant | 9.9k | — | — | May 1, 2026 |
| RECHTIN JAMES A.Chief Executive Officer | Grantindirect | 35.6k | — | — | May 1, 2026 |
| SHETTY SANJAY KOfficer | Other | 887 | — | — | Apr 1, 2026 |
| VENTURA JOSEPH CHRISTOPHEROfficer | Other | 1.0k | — | — | Feb 24, 2026 |
| FELTER JOHN- PAUL W.Officer | Other | 165 | — | — | Feb 24, 2026 |
| RENAUDIN GEORGE IIOfficer | Other | 1.0k | — | — | Feb 24, 2026 |
| SHETTY SANJAY KOfficer | Buy | 810 | $185.20 | $150k | Feb 23, 2026 |
| FELTER JOHN- PAUL W.Officer | Grant | 5.7k | — | — | Feb 23, 2026 |
| DINTENFASS DAVIDOfficer | Other | 3.9k | — | — | Feb 20, 2026 |
No analyst notes on HUM yet.
Analyst Ratings
24 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 13 | 9 | 1 | 0 | Buy2.31 |
| 1 mo ago | 2 | 11 | 12 | 1 | 0 | Buy2.46 |
| 2 mo ago | 1 | 11 | 13 | 1 | 0 | Hold2.54 |
| 3 mo ago | 1 | 11 | 12 | 2 | 0 | Hold2.58 |
Members whose judged calls on HUM have played out most reliably.
No settled calls on HUM yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice